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BRAF inhibition sensitizes 
melanoma cells to α-amanitin 
via decreased RNA polymerase II 
assembly
Lukas Frischknecht1, Christian Britschgi1,3, patricia Galliker1, Yann Christinat  1, 
Anton Vichalkovski2, Matthias Gstaiger2, Werner J. Kovacs  1 & Wilhelm Krek1
Despite the great success of small molecule inhibitors in the treatment of patients with BRAFV600E 
mutated melanoma, the response to these drugs remains transient and patients eventually relapse 
within a few months, highlighting the need to develop novel combination therapies based on the 
understanding of the molecular changes induced by BRAFV600E inhibitors. the acute inhibition of 
oncogenic signaling can rewire entire cellular signaling pathways and thereby create novel cancer cell 
vulnerabilities. Here, we demonstrate that inhibition of BRAFV600E oncogenic signaling in melanoma 
cell lines leads to destabilization of the large subunit of RNA polymerase II POLR2A (polymerase RNA 
II DNA-directed polypeptide A), thereby preventing its binding to the unconventional prefoldin RpB5 
interactor (URI1) chaperone complex and the successful assembly of RNA polymerase II holoenzymes. 
Furthermore, in melanoma cell lines treated with mitogen-activated protein kinase (MAPK) inhibitors, 
α-amanitin, a specific and irreversible inhibitor of RNA polymerase II, induced massive apoptosis. 
Pre-treatment of melanoma cell lines with MAPK inhibitors significantly reduced IC50 values to 
α-amanitin, creating a state of collateral vulnerability similar to POLR2A hemizygous deletions. thus, 
the development of melanoma specific α-amanitin antibody-drug conjugates could represent an 
interesting therapeutic approach for combination therapies with BRAFV600E inhibitors.
Melanoma is an aggressive tumor with poor survival when disseminated to distant organs. In recent years, two 
main types of treatment have been developed for melanoma, which substantially helped to increase overall sur-
vival of patients: immune checkpoint inhibitors and targeted therapies1. BRAF-mutated metastatic melanoma has 
become a prototype for therapies targeting oncogenic activated signaling cascades. Several compounds inhibiting 
BRAFV600E and the downstream mitogen-activated protein kinase (MAPK) signal transduction pathway were 
developed and are now successfully used in the clinic2. However, these therapies are effective in only a subset of 
patients, approximately 50% with tumors harboring the gain-of-function BRAFV600E mutation, and drug resist-
ance inevitably develops and most patients relapse within a few months1,2.
The acute inhibition of oncogenic driver mutations by small molecule inhibitors can rewire entire signaling 
cascades within hours and might thereby increase the dependency on certain cellular functions3. A better mech-
anistic understanding of the acute response of cancer cells to inhibition of oncogenic signaling as well as their 
response to diverse intra- or extracellular stresses will help to elucidate novel cancer cell vulnerabilities and to 
develop combination therapies3–5.
Chaperone proteins are considered to be central nodes in cellular homeostasis. Through their transient 
interactions with diverse client proteins they are involved in several signaling pathways. Posttranslational mod-
ifications of the chaperone proteins themselves or of client proteins by oncogenic signaling can influence their 
interactions and thereby change the signaling output6–9. The unconventional prefoldin RPB5-interactor (URI1) 
is a member of the prefoldin family of evolutionary conserved molecular chaperones. It was shown to be a direct 
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phosphorylation target of p70-S6 kinase 1 (S6K1). This URI1 phosphorylation is controlling its interaction with 
the phosphatase PP1γ (protein phosphatase 1, catalytic subunit, gamma isoform) and thereby PP1γ-mediated 
de-phosphorylation of S6K18. Furthermore, it was demonstrated that URI1 is amplified and has oncogenic func-
tions in ovarian cancer by sequestration of PP1γ in an inactive complex, thus preventing the PP1γ-mediated 
negative feedback and shifting the apoptotic balance towards increased survival10. In addition, a subset of URI1 
non-amplified colorectal cancer (CRC) cell lines has developed a strong dependency on the URI1 chaperone 
system11.
URI1 is an evolutionary conserved interactor of POLR2E (polymerase RNA II DNA-directed polypeptide E, 
also known as RPB5), a shared subunit of all three RNA polymerases12–14. Together with its co-members of the 
URI1/‘prefoldin-like’ and the R2TP [RUVBL1, RUVBL2, RPAP3 (in yeast known as Tah1), PIH1D1] complex it 
is tightly involved in the cytoplasmic assembly of all three RNA polymerase complexes13,15–17.
Recently, transcription and RNA polymerases have become interesting novel therapeutic targets18,19. In 
2015 Liu et al.18 showed that colorectal cancer cell lines with only one allele of POLR2A (polymerase RNA II 
DNA-directed polypeptide A) and therefore lower POLR2A protein levels demonstrate an increased sensitivity 
to α-amanitin, a selective and specific inhibitor of RNA polymerase II. Furthermore, they showed that POLR2A 
as a flanking gene of the tumor suppressor gene TP53 on chromosome 17p, is co-deleted in approximately half of 
CRC cases18. α-amanitin, a cyclic peptide of eight amino acids, is a toxin found in the mushroom Amanita phal-
loides. In contrast to other transcription inhibitors, it binds to POLR2A with very high affinity, causes a transcrip-
tional arrest and leads to the degradation of POLR2A18,20,21. To circumvent its liver toxicity Liu et al. constructed 
an anti-epithelial cell adhesion molecule (EpCAM) antibody coupled to α-amanitin. Using this antibody-drug 
conjugate they were able to show complete tumor regressions in mouse models of human colorectal cancer with 
a hemizygous deletion of POLR2A18.
Given the strong dependency of several cancer cells throughout all cancer types on the URI1 chaperone com-
plex, its critical involvement in the RNA polymerase assembly and the direct influence of oncogenic signaling 
on URI1 interaction with client proteins, we investigated the effect of acute inhibition of BRAFV600E oncogenic 
signaling on the URI1 interactome in melanoma cells.
Results
Inhibition of oncogenic BRAFV600E decreases interaction of RNA polymerase II subunits with 
the chaperone URI1 in melanoma cell lines. We performed a mass spectrometry analysis to investi-
gate whether BRAFV600E oncogenic signaling might influence interactions of the URI1 chaperone complex with 
client proteins in melanoma cell lines. For this purpose the BRAFV600E-mutated melanoma cell line A375-P was 
treated with 1 μM of the vemurafenib analogue PLX4720 for 16 h, followed by URI1 immunoprecipitation and 
proteomics analysis. The PLX4720 concentration was chosen based on the data of the original description of 
PLX4720 as well as experience in our lab showing the best phospho-ERK suppression without induction of mas-
sive apoptosis22. Supplementary Table 1 shows all URI1 interactors with their respective spectral counts detected 
in our proteomics analysis. Apart from the members of the URI1/‘prefoldin-like’ and the R2TP chaperone 
complexes, we detected several subunits of the three nuclear RNA polymerases, as well as other transcription 
regulatory proteins like the PAF1 (Polymerase-Associated Factor 1) complex. Furthermore, all three isoforms 
of protein phosphatase 1 were detected. Acute inhibition of BRAFV600E did not affect the composition of the 
URI1 core-chaperone complex (i.e., the ‘prefoldin-like’ and R2TP complex members: URI1, STAP1, PDRG1, 
PFD2, PFD6, RUVBL1, RUVBL2, RPAP3, PIH1D1, WDR92 and POLR2E) nor its association with transcription 
regulatory proteins. However, the interaction with most RNA polymerase subunits that were detected strongly 
decreased upon PLX4720 treatment. This was especially prominent for the subunits of RNA polymerase II 
(Fig. 1A and Supplementary Table 1). Furthermore, the gamma isoform of protein phosphatase 1 only bound to 
URI1 when BRAFV600E signaling was inhibited (Supplementary Table 1), similar as already described for PP1γ 
binding to URI1 when S6K1 signaling is inhibited8. To confirm the observed effect of BRAFV600E inhibition on 
URI1 interaction with RNA polymerases, we performed URI1 co-immunoprecipitation experiments in a panel 
of BRAFV600E-mutated melanoma cell lines (A375-P, A2058, SK-MEL-28 and UACC-62) treated with PLX4720 
for 24 h and blotted for each of the large subunits of the three nuclear RNA polymerases POLR1A, POLR2A and 
POLR3A [polymerase RNA (I, II, III) DNA-directed polypeptide A]. The large subunits thereby served as a rep-
resentative of the corresponding RNA polymerase complex. Only URI1 interaction with POLR2A consistently 
decreased in three out of four melanoma cell lines (Fig. 1B). Interaction with STAP1 (SKP2-Associated Alpha 
PFD 1), a member of the URI1/‘prefoldin-like’ complex, was not changed in any of the cell lines upon BRAFV600E 
inhibition (Fig. 1B). This finding was confirmed in A375-P and UACC-62 cell lines with the MEK1/2 inhibitor 
AZD6244, which showed similar results in both cell lines as we observed with PLX4720 (Figs 1C, S1B and S2). 
To further assess the dynamics of URI1/POLR2A interaction upon BRAFV600E inhibition, we treated A375-P cells 
for 12, 16, 20, 24 and 48 h with PLX4720. A steady decrease of POLR2A binding to URI1 was observed (Fig. 1D). 
This decreased interaction was accompanied by a reduction in POLR2A protein levels in PLX4720-treated cells, 
which occurred concomitantly with the decrease of URI1/POLR2A complex abundance (Fig. 1D). The well-
known reactivation of ERK-signaling after prolonged PLX4720 treatment23,24 did not lead to an up-regulation of 
POLR2A protein levels or increase of URI1/POLR2A complexes (Fig. 1D). Furthermore, POLR2A mRNA expres-
sion in A375-P and UACC-62 cells did not change upon PLX4720 treatment, thereby excluding a direct effect of 
inhibiting the ERK-signaling pathway on POLR2A transcription, whereas mRNA levels of the ERK target genes 
SPRY2 (sprouty homolog 2) and CCND1 (cyclin D1) were decreased in PLX4720-treated cells (Figs 1E and S2B).
POLR2A is destabilized by inhibition of oncogenic BRAFV600E signaling. To study the reason for 
the observed POLR2A downregulation under BRAFV600E inhibition, we inhibited proteasomal degradation with 
Bortezomib in A375-P cells treated with PLX4720 for 48 h. Bortezomib, added for 16 h, stabilized POLR2A 
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Figure 1. Inhibition of oncogenic BRAFV600E decreases interaction of RNA polymerase II subunits with 
the chaperone URI1 in melanoma cell lines. (A) Mass-spectrometric analysis of URI1 interaction partners 
in A375-P cells treated for 16 hours with 1 μM PLX4720 (PLX) (red) or DMSO control (blue). Shown are 
the spectral counts of the URI1 core chaperone complex (logarithmic scale) and of the four subunits of 
RNA polymerase II, that were detected (linear scale). (B) Representative immunoblot showing URI1 co-
immunoprecipitation of A375-P, A2058, SK-MEL-28 and UACC-62 cells treated with PLX4720 or DMSO as 
control for 24 hours. (C) Representative URI1 co-immunoprecipitation of A375-P cells treated with 1 μM of the 
BRAFV600E inhibitor PLX4720. The lower panel shows the respective input lysates. (D) Representative URI1 co-
immunoprecipitation of A375-P cells treated for the indicated time points with 1 μM PLX4720. The lower panel 
shows the respective input lysates, p-ERK and total ERK served as a treatment and loading control (n = 3). (D) 
Expression of POLR2A and the ERK target genes SPRY2 and CCND1 after indicated time of PLX4720 treatment 
in A375-P cells. Each value represents the amount of mRNA relative to that in DMSO-treated cells, which was 
arbitrarily defined as 1. Data are mean ± SD (n = 3 biological replicates).
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both in DMSO- and PLX4720-treated cells to comparable levels (Fig. 2A). Furthermore, Bortezomib-stabilized 
POLR2A was able to bind to the URI1 chaperone (Fig. 2B). These data indicate that POLR2A binding to the URI1 
complex mainly depends on POLR2A protein stability.
Blocking de novo protein synthesis with cycloheximide in A375-P cells demonstrated a rather short half-life 
of POLR2A. In cells treated with PLX4720 the protein half-life was even decreased (Fig. 2B). In contrast, the 
stability of URI1 and the URI1 interactor POLR2E was not affected by cycloheximide nor by PLX4720 treatment. 
The downregulation of p53 upon cycloheximide treatment was immediate and not affected by PLX4720. These 
data suggest that BRAFV600E oncogenic signaling controls POLR2A protein stability and, by this, RNA polymerase 
II levels. Shutdown of this signaling pathway in melanoma cell lines leads to a decrease of POLR2A stability and 
therefore diminishes its protein levels over time.
α-amanitin induces massive cell death of PLX4720-treated melanoma cell lines. Since inhibi-
tion of oncogenic BRAFV600E signaling in melanoma cells decreased POLR2A stability, we investigated whether 
the RNA polymerase II inhibitor α-amanitin might exhibit synergistic effects in combination with PLX4720. 
Therefore, we treated the three BRAFV600E-mutated melanoma cell lines A375-P, UACC-62 and WM-266-4 either 
with α-amanitin alone or in combination with PLX4720 for 72 hours and assessed POLR2A protein levels as well 
as PARP and Caspase-3 cleavage by western blot (Fig. 3A–C). Based on the data of Liu et al. in CRC cell lines18 
with hemizygous POLR2A deletions we chose low concentrations of α-amanitin (0.25 μg/ml for UACC-62 and 
WM-266-4 and 1 μg/ml for the more resistant A375-P). Whereas α-amanitin alone had only modest effects on 
POLR2A levels and cleavage of apoptotic proteins, the combination with PLX4720 almost completely abolished 
POLR2A and caused a massive cleavage of PARP and Caspase-3 as well as an up-regulation of p53 (Fig. 3A–C). 
In addition, apoptosis was quantified by flow cytometry using Annexin V/propidium-iodide (PI) double staining 
(Fig. 3D–E and Supplementary Fig. 3A–C). The combination treatment significantly increased apoptotic cell 
death in all the three cell lines tested. In contrast, the combination of PLX4720 and α-amanitin did not increase 
the apoptotic rate in the BRAF- and NRAS-wildtype melanoma cell line MeWo (Fig. S3D,E).
Inhibition of oncogenic activated MApK signaling creates a collateral vulnerability towards 
α-amanitin similar as POLR2A hemizygous deletion. Liu et al. (2015) showed that CRC cell lines 
with only one allele of POLR2A and therefore lower POLR2A protein levels show an increased sensitivity to 
α-amanitin18. As POLR2A is a flanking gene of the tumor suppressor gene TP53 on chromosome 17p, it is 
Figure 2. POLR2A is destabilized by inhibition of oncogenic BRAFV600E signaling. (A) Representative 
immunoblot of A375-P treated with PLX4720 or DMSO for 48 hours. During the last 16 hours both PLX4720 
and DMSO samples were treated with the proteasome inhibitor Bortezomib or vehicle control (n = 3). 
α-Tubulin served as a loading control. (B) URI1 co-immunoprecipitation of lysates described in (A) (n = 3). 
(C) Representative immunoblot of A375-P cells treated with PLX4720 or DMSO control for 16 hours, followed 
by cycoheximide treatment for the indicated timepoints. The lower panel shows the quantification of three 
independent biological replicates, normalized to the respective 0 CHX timepoint and α-Tubulin loading control 
(mean ± SD).
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co-deleted in approximately half of CRC cases18. In melanoma TP53 deletions are not as frequent as they are in 
CRC. However, hemizygous deletions of TP53 and therefore POLR2A can be found in around one third of mela-
noma cases according to the TCGA database (http://portals.broadinstitute.org/tcga/home). Based on data from 
the Cancer Cell Line Encyclopedia (CCLE) database we chose two melanoma cell lines with a hemizygous dele-
tion of POLR2A and two control cell lines with two POLR2A copies25. Similar as in CRC, melanoma cell lines with 
Figure 3. α-amanitin induces massive cell death in PLX4720-treated melanoma cell lines. (A–C) 
Representative immunoblots for POLR2A and apoptosis markers in indicated melanoma cell lines treated with 
α-amanitin (1 μg/ml in A375-P and 0.25 μg/ml in UACC-62 and WM-266-4) alone or in combination with 
1 μM PLX4720 (n = 3). P-MEK, total MEK and α-Tubulin served as a treatment and loading control. (D–F) 
Apoptosis measurements of indicated melanoma cell lines by Annexin V-FITC and propidium iodide double 
staining after treatment with α-amanitin alone or in combination with PLX4720. Percentage of Annexin V 
positive cells for each condition is displayed. Data are mean ± SD (n = 3 biological replicates).
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a hemizygous loss of POLR2A (i.e., IGR-37, SK-MEL-2) had significantly lower levels of POLR2A mRNA and pro-
tein than the POLR2A copy neutral cell lines A375-P and UACC-62 (Fig. 4A,B). To assess if the former are more 
sensitive to α-amanitin, we performed α-amanitin dose response curves. Indeed, both IGR-37 and SK-MEL-2 
cells showed significantly lower IC50 values, 269.4 ng/ml (95% CI, 226.5 to 320.4 ng/ml) and 156.8 (95% CI, 
141.1 to 174.1 ng/ml) respectively, compared to A375-P and UACC-62 cells with IC50 values of 1248 ng/ml 
(95% CI, 953.7 to 1632 ng/ml) and 581.7 ng/ml (95% CI, 478.0 to 707.9 ng/ml), respectively (Fig. 4C). Given the 
effect of BRAFV600E and MEK1/2 inhibitors on POLR2A protein levels we examined whether the addition of a 
MAPK inhibitor would influence the IC50 values to α-amanitin independent of the POLR2A copy number status. 
Therefore, we treated the POLR2A loss and neutral cell lines SK-MEL-2 and A375-P, respectively, with a MAPK 
inhibitor followed by treatment with different α-amanitin concentrations. Indeed, treatment of SK-MEL-2 
(POLR2A loss; NRASQ61R) and A375-P (POLR2A neutral; BRAFV600E) with AZD6244 or PLX4720, respectively, 
increased the α-amanitin sensitivity significantly (IC50: 226.6 (95% CI, 210.3 to 244.1) vs. 73.88 (95% CI, 69.09 
to 79.00) ng/ml and 1845 (95% CI, 1108 to 3070) vs. 427.2 (95% CI, 331.2 to 551.1) ng/ml respectively) (Fig. 4D).
Discussion
In this study we describe a novel vulnerability of melanoma cell lines treated with MAPK inhibitors to the RNA 
polymerase II inhibitor α-amanitin. The underlying cause of this vulnerability is most likely a destabilization of 
the large RNA polymerase II subunit POLR2A by blocking oncogenic ERK signaling. Furthermore, our study 
sheds light onto how ERK signaling controls the assembly of RNA polymerase II holoenzymes.
In contrast to CDK9 (Cyclin-dependent kinase 9) inhibitors, α-amanitin not only transiently inhibits the 
transcription machinery but also leads to the degradation of POLR2A20,21. This might explain its synergistic effect 
on apoptosis induction observed in combination with MAPK inhibition in melanoma cells. Indeed, the com-
bination of the CDK9 inhibitor Alvocidib with PLX4720 did not have the same effect as α-amanitin combined 
with PLX4720 (Supplementary Fig. 4). Since cell growth and proliferation increase the transcription rate of a 
cell26, it has to augment the availability of its transcription machinery. Here we present evidence that oncogenic 
Figure 4. Inhibition of oncogenic activated MAPK signaling creates a collateral vulnerability towards 
α-amanitin, similar as POLR2A hemizygous deletion. (A) POLR2A expression in melanoma cell lines with 
two copies of POLR2A (A375-P, UACC-62) or a monoallelic loss of one copy (IGR-37, SK-MEL-2). Each value 
represents the amount of mRNA relative to that in A375-P cells, which was arbitrarily defined as 1. TBP was 
used as the invariant control. Data are mean ± SD (n = 3 biological replicates). (B) Representative immunoblot 
for POLR2A in melanoma cell lines used in (A) (n = 3). α-Tubulin served as a loading control. (C) Drug 
response curves of indicated melanoma cell lines treated with increasing concentrations of α-amanitin. Data 
are mean ± SD (n = 3 biological replicates). (D) Drug response curves to α-amanitin of A375-P and SK-MEL-2 
pre-treated (for 16 h) either with the indicated MAP-Kinase inhibitor or DMSO as control. Data are mean ± SD 
(n = 3 biological replicates).
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activated ERK signaling does this at least in part by controlling the stability of the large RNA polymerase II sub-
unit POLR2A.
Theoretically, the dependency of a BRAFV600E inhibitor-treated quiescent cell on transcription should 
decrease. However, there might be a certain threshold of POLR2A protein levels necessary for cell survival and 
the combined effects of acute BRAFV600E inhibition and α-amanitin treatment inducing POLR2A degradation 
could push cells towards apoptosis.
Due to its strong liver toxicity α-amanitin cannot be used in vivo, unless it is administered as an antibody-drug 
conjugate. Liu et al. conjugated α-amanitin to an anti-epithelial cell adhesion molecule (EpCAM) antibody and 
demonstrated complete tumor regression in mouse models of human colorectal cancer with a hemizygous loss of 
POLR2A18. The development of a melanoma-specific α-amanitin antibody-drug conjugate and its combination 
with BRAFV600E inhibitors in preclinical melanoma models will be an important next step to further validate our 
findings. Antibodies targeting the transmembrane protein GPNMB (glycoprotein NMB) are the best character-
ized targets for antibody-drug conjugates in melanoma27 Indeed, for in vivo studies GPNMB antibodies coupled 
to α-amanitin might be an ideal candidate for a combination with a BRAFV600E inhibitor, as GPNMB expression 
seems to slightly increase in PLX4720-treated cells (Supplementary Fig. 5). However, the safety of α-amanitin 
coupled to an antibody in humans is so far unknown because of a lack of clinical studies and has to be carefully 
addressed. Taken together, combining α-amanitin with BRAFV600E inhibitors could potentially help to induce an 
apoptotic response in otherwise quiescent melanoma cells that represent a reservoir for the subsequent develop-
ment of resistance to BRAFV600E inhibition alone.
Materials and Methods
Cell lines and culture. Cells were cultivated at 37 °C in 21% O2 and 5% CO2 in a humidified incubator. 
The following melanoma cell lines and culture media were used: A375-P (R. Hynes, MIT), WM-266-4, A2058, 
SK-MEL-28, SK-MEL-2, MeWo and HEK-293T cells (ATCC) were cultured in Dulbecco’s modified Eagle’s 
medium (DMEM) supplemented with 10% FCS (Ambimed), 2 mM L-glutamine (Gibco) and 1% non-essential 
amino acids (NEAA; Gibco). UACC-62 cells (NCI-60) were cultured in RPMI-1640 medium supplemented with 
10% FCS and GlutaMax (Gibco). IGR-37 cells (ATCC) were cultured in DMEM supplemented with 15% FCS.
All cell lines were regularly tested for mycoplasma contamination with a PCR-based assay (A8994; 
AppliChem). Cell line profiling was performed using highly-polymorphic short tandem repeat loci (STRs) and 
the DNA profile was compared with databases (Microsynth).
Reagents. PLX4720 (S2807), AZD6244 (S1008), Bortezomib (S1013) and Alvocidib (S2679) were purchased 
from Selleck Chemicals and dissolved in DMSO (dimethyl sulfoxide) as 1 or 10 mM stock solutions and stored 
at −80 °C. Cycloheximide (Sigma-Aldrich) was dissolved in water as a 50 mM stock solution and stored at 4 °C. 
α-amanitin (A2263; Sigma-Aldrich) was dissolved in water as 1 mg/ml stock solution and stored at −20 °C.
Cell lysis, immunoblotting and antibodies. Cells were washed twice with ice-cold phosphate-buffered 
saline (PBS), scraped from the dish, transferred to an Eppendorf tube and centrifuged at 2400 rpm in a tabletop 
centrifuge for 5 min; for apoptosis experiments cell culture supernatants were collected and combined with cells 
which were harvested by trypsinization. Cell pellets were lysed in TNN buffer (50 mM Tris, pH 7.5; 250 mM NaCl; 
5 mM EDTA; 0.5% NP-40; 50 mM NaF; 0.5 mM EGTA) containing protease and phosphatase inhibitors (cOm-
plete and PhosSTOP, respectively; Roche) for 20 min on ice. The samples were centrifuged at full-speed in a table-
top centrifuge for 10 min and protein concentrations were determined using the Bradford assay (Bio-Rad). Protein 
concentrations were adjusted using TNN and 5x Laemmli buffer and boiled at 95 °C for 5 min. Equal amounts 
of proteins were separated by SDS-PAGE (sodium dodecyl sulfate polyacrylamide gel electrophoresis) using 
4–20% Mini-PROTEAN TGX Stain-Free Gels (Bio-Rad) and transferred to Trans-Blot Turbo PVDF Transfer 
Packs (Bio-Rad) using the Trans-Blot® TurboTM system (Bio-Rad). Membranes were blocked with 5% milk in 
Tris-buffered saline containing 0.05% Tween 20 (TBST) and incubated with the primary antibody over-night at 
4 °C. After washing with TBST, incubation with the corresponding horseradish peroxidase-conjugated secondary 
antibodies (Invitrogen®) was performed for 1 h at room temperature, membranes were washed again in TBST, 
developed using a homemade ECL solution and visualized on the ImageQuant LAS4000® mini (GE Healthcare).
The URI1 (mAb 58.1) and STAP1/UXT (mAb 105.128) monoclonal antibodies have been described previ-
ously and were used in a 1:100 dilution14. p44/42 MAPK (Erk1/2) (#9102), Phospho-p44/42 MAPK (Erk1/2) 
(Thr202/Tyr204) (#9101), MEK1/2 (#9122), Phospho-MEK1/2 (Ser217/221) (#9121) and Cleaved Caspase-3 
(#9664) antibodies were purchased from Cell Signaling Technology and used in a 1:1000 dilution. Alpha-tubulin 
(ab18251) (1:2000), POLR1A (ab139130) (1:500) and POLR3A (ab96328) (1:500) were purchased from Abcam, 
PARP (556362) (1:1000) and p53 (554293) (1:1000) from BD Pharmingen, POLR2A (39097) (1:1000) from 
Active Motif, and POLR2E (3B5) (NBP2-00482) (1:1000) from Novus Biologicals.
RNA extraction, cDNA preparation and quantitative real-time RT-PCR (qPCR). Total RNA was 
isolated from cultured cells using the NucleoSpin RNA II kit (Macherey-Nagel) according to the manufactur-
er’s instructions. RNA concentration was determined using a NanoDrop 2000 (Thermo Scientific). 1 or 2 μg of 
total RNA were reverse transcribed using the High-Capacity RNA-to-cDNA™ Kit (Cat. No. 4368813; Applied 
Biosystems) according to the manufacturer’s instruction and the cDNA was diluted to 5 ng/μl. For qPCR a 20 μl 
reaction mix was prepared in a Roche LightCycler 480 Multiwell Plate (1 μl 5 μM forward primer, 1 μl 5 μM 
reverse primer, 10 μl KAPA SYBR® FAST, 3 μl water and 5 μl cDNA) and run on a Roche LightCycler LC480, using 
the following program: 5 min pre-incubation at 95 °C, 45 amplification cycles (10 sec. 95 °C, 10 sec. 60 °C, 10 sec. 
72 °C). A melt curve analysis was carried out to confirm the specific amplification of a target gene and absence 
of primer dimers. Relative mRNA amount was calculated using the comparative threshold cycle (CT) method. 
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TBP (TATA-box binding protein) was used as the invariant control. The following primer pairs were used: TBP 
(forward: 5′-TTCGGAGAGTTCTGGGATTGT-3′; reverse: 5′-TGGACTGTTCTTCACTCTTGG-3′); SPRY2 
(forward: 5′-ATCAGATCAGAGCCATCCGAA-3′; reverse: 5′-TGGAGTCTCTCGTGTTTGTGC-3′); CCND1 
(forward: 5′-GAACAAACAGATCATCCGCAAAC-3′; reverse: 5′-GCGGTAGTAGGACAGGAAGTTG-3′); 
POLR2A (forward: 5′-CATCAAGAGAGTCCAGTTCGG-3′; reverse: 5′-CCCTCAGTCGTCTCTGGGTA-3′).
URI1 co-immunoprecipitation. Cell lysis was performed as described above. Lysates were precleared with 
100 μl of recombinant Protein G Agarose (ThermoFisher Scientific) for 30 min on a slowly rotating wheel at 4 °C. 
After preclearing 900 μg of total protein was mixed with 2 μg of the anti-URI1 monoclonal antibody (clone 179-
2-1)14 or mouse IgG control, the volume adjusted to 500 μl with TNN and incubated for 2 h on a slowly rotating 
wheel at 4 °C. After adding 100 μl of Protein G Agarose the samples were incubated for another hour and subse-
quently washed four times with 900 μl TNN buffer. Finally, 10 μl of 5x Laemmli buffer was added to the Agarose, 
samples were vortexed for 15 sec and boiled at 95 °C for 5 min.
Apoptosis assays by Annexin V and Propidium iodide staining. Cells treated with α-amanitin for 
72 hours and the control cells were harvested by trypsinization collecting all supernatants, washed twice with 
ice-cold PBS and incubated with Annexin V-FITC conjugate (A13199; ThermoFisher Scientific)-containing 
Annexin V binding buffer (10 mM Hepes/NaOH, pH 7.4; 140 mM NaCl; 2.5 mM CaCl2) for 15 min at room tem-
perature. Propidium Iodide (PI) was added just prior to analysis by flow cytometry. Stained cells were analyzed 
using a BD Accuri™ C6 counting 10’000 events per sample. Unstained and single stained controls were included 
for color compensation. The data were analyzed using FlowJo software (Tree Star, Inc.).
Dose-response curves. For dose-response curves 1’500 cells or 4’500 cells (PLX4720 and AZD6244 treated 
plates) were seeded in a 96-well plate. On the following day nine different α-amanitin or Alvocidib concentrations 
plus treatment control were added and incubated for 72 hours. After the incubation period cells were washed four 
times with PBS using a HydroSpeed™ plate washer (TECAN) and incubated for 30 min at 37 °C and 5% CO2 with 
PrestoBlue® Cell Viability Reagent (A13262; ThermoFisher Scientific) diluted 1:10 in PBS. The converted fluo-
rescent dye was measured using the Infinite® M1000 PRO microplate reader (TECAN). Values were normalized 
to solvent control.
URI1 mass spectrometry. URI1 co-immunoprecipitation was performed as described with URI1 antibody 
coupled to recombinant Protein G Agarose. 5 mg of lysate were used for URI1 IP/IgG control of PLX4720 and 
DMSO control samples. Samples were incubated for 4 hours in 15 ml Falcon tubes on a slowly rotating wheel fol-
lowed by washing of the Agarose. The resuspended Agarose was loaded on Micro Bio-Spin® columns (Bio-Rad) 
and washed four times with 1 ml TNN buffer followed by another four times with 1.5 ml of a detergent free 
TNN buffer until bubbles were completely removed. Elution was performed with 150 μl 1 M glycine (pH 2.5). 
Immediately after elution, the eluates were neutralized with 5 μl 1 M NH4HCO3 (pH 8.8) and pH was verified 
with pH-indicator strip (Merck). 200 mM Tris(2-carboxyethyl)phosphine (TCEP) in NH4CO3 was added to the 
eluates and samples were incubated at 37 °C for 40 min, followed by 200 mM iodoacetamide to a final concentra-
tion of 10 mM and incubation at room temperature for 30 min in the dark. For peptide digestion 1 μg of trypsin 
(Sequencing Grade Modified Trypsin, Promega) was added to the eluates and incubated at 37 °C overnight. The 
next day, acidification of the samples with 10% formic acid was performed to reach a pH of 2–3 as tested with 
pH-indicator strips. 50% acetonitrile (ACN) was added to a final concentration of 1%. Next, samples were loaded 
on prepared Ultra-Micro SpinColumnsTM (Harward), washed three times with 200 μl 0.1% formic acid/5% ACN 
and peptides were eluted with 100 μl 0.1% formic acid/50% ACN. Samples were immediately processed to MS. 
LC-MS/MS was performed as previously described28.
Progenesis software (version 4.1; Nonlinear Dynamics, Newcastle, UK) was used for intensity-based label-free 
quantification. After selecting one sample as a reference, the retention times of all eluting precursor m/z values in 
all other samples within the experiment were aligned creating a list of “features” representing the same peptide 
in each sample. Features with two to six charges were included for further analysis. After alignment and feature 
filtering, replicate samples were grouped together, and raw abundances of all features were normalized. Briefly, 
for each sample, one unique factor is calculated and used to correct all features in the sample for experimental 
variation. Filtered peptide–spectrum matches (1% peptide–spectrum match FDR) were imported into Progenesis 
and matched to the respective features.
Data presentation and analysis. Prism 6 software (GraphPad Software Inc.) was used for all statistical 
analyses and data presentations.
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